scholarly journals Hypoxia-Inducible Factors: Mediators of Cancer Progression; Prognostic and Therapeutic Targets in Soft Tissue Sarcomas

Cancers ◽  
2013 ◽  
Vol 5 (4) ◽  
pp. 320-333 ◽  
Author(s):  
Navid Sadri ◽  
Paul Zhang
Keyword(s):  
Soft Tissue ◽  
Cancer Progression ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Hypoxia Inducible Factors

scholarly journals Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas

2019 ◽  
Vol 15 (2) ◽  
pp. e1006826 ◽  
Author(s):  
David G. P. van IJzendoorn ◽  
Karoly Szuhai ◽  
Inge H. Briaire-de Bruijn ◽  
Marie Kostine ◽  
Marieke L. Kuijjer ◽  
...  
Keyword(s):  
Gene Expression ◽  
Machine Learning ◽  
Soft Tissue ◽  
Gene Expression Data ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Prognostic Biomarkers ◽  
Expression Data ◽  
Learning Analysis

scholarly journals The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets

2014 ◽  
Vol 34 (6) ◽  
Author(s):  
Laura Rocchi ◽  
Stefano Caraffi ◽  
Roberto Perris ◽  
Domenica Mangieri
Keyword(s):  
Soft Tissue ◽  
Tumour Growth ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Specific Target ◽  
Target Therapies ◽  
New Therapeutic Targets

Angiogenesis is important for tumour growth and metastatization. The better understanding of the mechanisms of angiogenesis in soft tissue sarcomas can lead the design of specific target therapies for this group of poorly responding tumours.

scholarly journals Therapeutic Targets for Bone and Soft-Tissue Sarcomas

2019 ◽  
Vol 20 (1) ◽  
pp. 170 ◽  
Author(s):  
Shinji Miwa ◽  
Norio Yamamoto ◽  
Katsuhiro Hayashi ◽  
Akihiko Takeuchi ◽  
Kentaro Igarashi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Checkpoint Inhibitors ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Science Research ◽  
New Drugs ◽  
Basic Studies ◽  
Molecular Therapeutic ◽  
New Treatments ◽  
Molecular Therapeutic Targets

Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into molecular targets and new treatments has been particularly challenging. Although intensive chemotherapy and establishment of surgical procedures have improved the outcomes of patients with sarcoma, the curative rate of recurrent and metastatic sarcomas is still not satisfactory. Recent basic science research has revealed some of the mechanisms of progression and metastasis of malignancies including proliferation, apoptosis, angiogenesis, tumor microenvironment, migration, invasion, and regulation of antitumor immune systems. Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas.

scholarly journals Expression of IL4Rα and IL13Rα1 Are Associated With Poor Prognosis of Soft-tissue Sarcoma of the Extremities, Superficial Trunk, and Retroperitoneum 

2020 ◽  
Author(s):  
Kyoung Min Kim ◽  
Usama Khamis Hussein ◽  
See-Hyoung Park ◽  
Young Jae Moon ◽  
Zhongkai Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Cancer Progression ◽  
Univariate Analysis ◽  
Soft Tissue Sarcomas ◽  
Prognostic Indicators ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Human Soft Tissue

Abstract BackgroundIL4Rα and IL13Rα1 are constituents of the type II IL4 receptor. Recently, IL4Rα and IL13Rα1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Rα and IL13Rα1 in soft-tissue sarcomas have been limited. MethodsThis study investigated the expression of IL4Rα and IL13Rα1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum. ResultsIn human soft-tissue sarcomas, immunohistochemical expression of IL4Rα was significantly associated with IL13Rα1 expression. Nuclear and cytoplasmic expression of IL4Rα and IL13Rα1 were significantly associated with shorter survival of soft-tissue sarcoma patients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Rα and IL13Rα1 were independent indicators of shorter overall survival (IL4Rα; p = 0.002, IL13Rα1; p = 0.016) and relapse-free survival (IL4Rα; p = 0.022, IL13Rα1; p < 0.001) of soft-tissue sarcoma patients. Moreover, the co-expression pattern of nuclear IL4Rα and IL13Rα1 was an independent indicator of shorter survival of soft-tissue sarcoma patients (overall survival; overall p < 0.001, relapse-free survival; overall p < 0.001). ConclusionsThis study suggests IL4Rα and IL13Rα1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Rα and IL13Rα1 might be novel prognostic indicators of soft-tissue sarcoma patients.

LOCAL RECURRENCES AFTER THE TREATMENT OF SOFT TISSUE MALIGNANT FIBROUS HISTIOCYTOMA (UNCLASSIFIEDPLEOMORPHIC SARCOMA) OF THE LIMBS

2019 ◽  
Vol 72 (8) ◽  
pp. 1523-1526
Author(s):  
Oleksandr O. Lytvynenko ◽  
Volodymyr F. Konovalenko ◽  
Anton Yu. Ryzhov
Keyword(s):  
Soft Tissue ◽  
Malignant Fibrous Histiocytoma ◽  
Fibrous Histiocytoma ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Primary Treatment ◽  
Radical Excision ◽  
Local Recurrences ◽  
Results Of Treatment

Introduction: The treatment of patients with malignant fibrous histiocytoma as well as other soft tissue sarcomas is not sufficiently effective up to date, and has largely changed and reflects the alterations, occurred in oncology as a whole. The number of amputation decreased over the last 10-15 years. Some researchers associate the improvement of treatment outcomes with the development of combined and complex methods. The aim of the study is an improvement of the results of treatment of patients with soft tissue malignant histiocytoma on the basis of determination of factors, influencing local recurrence development. Materials and methods: The basis of our study was a comprehensive analysis of examination and treatment results of 130 patients with MFH of the soft tissue of limbs, of them in 84 patients (64.6%) the recurrences developed. The group included 45 (53.6%) males and 39 (46.4%) females. The major part of patients – 82.1% (60 patients) were older than 40 years. Results and conclusions: The number of recurrences after the treatment in general surgical facilities is 86.9%, whereas in the patients after the treatment in the specialized oncological facilities this figure is twice lower (40%). The characteristic of the medical facility where the patient receives his/her primary treatment largely affects the development of local recurrences, patients’ quality of life and overall survival rates. The surgical method remains the leading modality in the treatment of MFH of ST. Wide and radical excision of tumors in the specialized oncological facilities allows achieving better survival outcomes of the patients.

Sign in / Sign up

Export Citation Format

Share Document